Spruce Biosciences Inc. (SPRB)
NASDAQ NASDAQ Primary 
SPRB ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Spruce Biosciences, Inc. investment
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
Investors Who Have Incurred Losses Are Urged To Make Contact As The Schall Law Firm Investigates Spruce Biosciences Inc
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Who Have Suffered Losses Are Urged To Make Contact As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates
Spruce Biosciences, Inc. (SPRB) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.32 per share a year ago.
Investors With Losses Are Encouraged To Reach Out As Spruce Biosciences Inc Is Under The Schall Law Firm's Investigation
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses Are Urged To Make Contact As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Who Have Incurred Losses Are Encouraged To Reach Out As Spruce Biosciences Inc Is Under Investigation By The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses Are Urged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses Are Urged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses Are Urged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
